Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Quick Recap

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Mar 05, 2021 9:43am

84 Views

Post# 32726778

RE:RE:Quick Recap

AngelaL wrote: Your comment is nothing but rubbish. The company has a bulletproof license for R-107 as a treatment for Covid (read it, you can find it on Sedar). It would have nice to have acquired all of Salzman Group but that would have come at the price of a hefty dilution. The PR this week describing the strategic collaboration augurs well for a tight relationship where Claritas has all the benefits of the scientific prowess of the Salzman Group without having to have acquired them and diluted. So take a deep breath and relax. The way things are looking, the SP is headed to the moon and for good reason.

Take a bow Angela!

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property